RecruitingNCT06940531
Identifying the Causes and Risk Factors of Pulmonary Exacerbations in Cystic Fibrosis
Studying Cystic fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alexander Horsley
- Enrollment
- 300 target
- Eligibility
- 5 years · All sexes
- Timeline
- 2025 – 2029
Study locations (17)
- Manchester Adult Cystic Fibrosis Centre, Manchester, Manchester, United Kingdom
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
- Blackpool Teaching Hospitals, Blackpool, United Kingdom
- Medical Research Unit, Bristol Royal Infirmary, Bristol, United Kingdom
- Cardiff and Vale University Health Board, Cardiff, United Kingdom
- Royal Devon and Exeter Hospital (Wonford), Exeter, United Kingdom
- NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
- Leeds Adult CF Centre, Leeds, United Kingdom
- Liverpool Heart & Chest Hospital, Liverpool, United Kingdom
- Chest Unit Reception, King's College Hospital, London, United Kingdom
- Royal Brompton Hospital, Department of Cystic Fibrosis (Adult), London, United Kingdom
- Newcastle Adult CF Centre, Newcastle upon Tyne, United Kingdom
- Nottingham City Hospital, Nottingham, United Kingdom
- John Radcliffe Hospital, Oxford, United Kingdom
- National Institute for Health Research Clinical Research Facility, Southampton, United Kingdom
- +2 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06940531 on ClinicalTrials.govOther trials for Cystic fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNANCT07436351ACT With CF Self-Help ToolkitThomas Jefferson University
- RECRUITINGNANCT07314229Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-IvacaftorUniversity Hospital, Lille
- RECRUITINGNCT07083557Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)Bettina Mittendorfer
- RECRUITINGNCT07369414Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at HomeResearch Center Borstel
- RECRUITINGNCT07505797ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)iSono Health, Inc.
- RECRUITINGPHASE1NCT07283770Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNCT07363304Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.Meyer Children's Hospital IRCCS